Background-Strategies for prevention of sudden cardiac death focus on severe left ventricular (LV) dysfunction, although most sudden cardiac death postmyocardial infarction occurs in patients with mild/moderate LV dysfunction. We tested the hypothesis that infarct heterogeneity by cardiac magnetic resonance is associated with mortality beyond LV ejection fraction (LVEF) in patients with coronary artery disease and LV dysfunction. In addition, we examined the association between infarct heterogeneity and mortality in those with LVEF >35%. Methods and Results-We studied 301 patients with coronary artery disease and LV dysfunction referred for cardiac magnetic resonance. We quantified total infarct mass, infarct core mass, and peri-infarct zone (PIZ) normalized for total infarct mass (%PIZ) using signal-intensity criteria of >2 SDs, >3 SDs, and 2-to -3 SDs above remote myocardium, respectively. Mean LVEF was 41±14%. After 3.9 years median follow-up, 66 (22%) patients died (13 sudden cardiac death; 33 with LVEF >35%). In patients with LVEF >35%, below-median %PIZ carried an annual death rate of 2.8% versus 12% in patients with above-median %PIZ (P<0.001). In a multivariable model, %PIZ maintained strong association with mortality adjusted to patient age, LVEF, right ventricular ejection fraction , prolonged QT interval, and total infarct size and resulted in improve risk reclassification 0.492 (95% confidence interval, 0.183-0.817). Conclusions-Cardiac magnetic resonance infarct heterogeneity has a strong association with mortality independent of LVEF in patients with coronary artery disease and LV dysfunction, particularly in patients with mild or moderate LV dysfunction. Further studies incorporating cardiac magnetic resonance in clinical decision making for defibrillator therapy are warranted. (Circ Cardiovasc Imaging. 2014;7:887-894.)
D espite the improved outcomes after acute myocardial infarction (MI), patients with post-MI left ventricular remodeling still harbor significant long-term risk of sudden cardiac death (SCD). Traditionally, clinicians have relied on left ventricular ejection fraction (LVEF) as a powerful and independent arbiter of clinical risk. 1 In current practice guidelines, the benefit of implantable-cardioverter defibrillator (ICD) placement for primary sudden death prevention is established in patients with an LVEF ≤30% to 35% in chronic coronary artery disease (CAD). 2, 3 Despite this focus on primary prevention in patients with severely reduced LV function (LVEF ≤35%), it is those patients with LVEF >35% who by absolute number account for the majority of sudden death post-MI. 4, 5 Moreover, there is increasing recognition that only approximately one fifth of those individuals who experience sudden cardiac arrest meet guideline recommendations for ICD implantation. 6 Furthermore, methods to stratify risk in this group (eg, signal averaged electrocardiography, microvolt T-wave alternans, baroreflex sensitivity, electrophysiological study) have limited sensitivity [7] [8] [9] with significant personal and economic consequences of misclassifying at-risk patients. Therefore, novel methods to stratify risk of mortality in this population are necessary.
Cardiac magnetic resonance (CMR) late gadolinium enhancement (LGE) imaging has been used to characterize tissue heterogeneity in peri-infarct myocardium. 10, 11 The peri-infarct zone (PIZ) mass had been associated with all-cause and cardiovascular mortality post-MI, independent of CMR infarct size and LVEF. 11 This finding was supported by several single-center studies associating the PIZ by CMR with arrhythmogenic substrates of serious ventricular arrhythmias. 10, 12 However, these studies were small in sample size and could not address the prognostic relevance of PIZ in patients with ischemic cardiomyopathy and an LVEF >35% who are currently not guideline eligible for more advanced therapies (ie, defibrillator placement). In this study, we sought to test the hypothesis that PIZ is associated with clinical outcomes in patients with CAD and LVEF >35% incremental to traditional markers of risk.
Methods

Patient Population
We studied a consecutive group of patients with a history of chronic CAD and left ventricular dysfunction. All patients were clinically referred for CMR assessment of myocardial viability alone (N=205, 68%), viability and ischemia (N=48, 16%), or evaluation of cardiomyopathy in addition to CAD (N=48, 16%). Inclusion criteria included patient age >21 years, definitive evidence of prior CAD, and LV dysfunction defined by LVEF <60% quantified by CMR. CAD was defined as either a history of MI confirmed in the medical record, significant angiographic coronary stenosis (>70% stenosis in ≥1 epicardial artery or >50% in left main artery), or a documented history of percutaneous coronary intervention and coronary artery bypass graft surgery. Exclusion criteria included any acute MI within 40 days, hazardous metallic devices for CMR, significant claustrophobia uncontrolled by sedatives, an estimated glomerular filtration rate ≤30 mL/min per 1.73 m 2 within 30 days before CMR, any presence of LGE consistent with nonischemic myocardial infiltration (diffuse, epicardial, or midwall pattern), decompensated heart failure prohibiting patients from lying flat during a CMR study, and any coexisting noncardiac condition that may limit survival to <1 year. The local institutional review board approved the study.
CMR Protocol
Patients underwent supine CMR in either a 1.5-T scanner (Signa CV/i General Electric Healthcare, Milwaukee, WI) with a 4-or 8-element phased-array surface coil or a 3.0-T scanner (Trio/Verio, Siemens, Erlangen, Germany) with a 12-element phased-array surface coil. All images were acquired with vector-cardiographic gating during breath-hold. Cine steady state free precession (typical repetition time, 3.4 ms; echo time, 1.2 ms; in-plane spatial resolution, 1.6×2.0 mm) was used for imaging LV size and function. LGE imaging was performed using a standard segmented inversion-recovery fast gradient echo sequence (repetition time, 4.8 ms; echo time, 1.3 ms; inversion time adjusted to null normal myocardium) for myocardial scar 10 to 15 minutes after ≥0.15 mmol/kg gadoliniumdiethylenetriaminepentacetate (Magnevist, Berlex Pharmaceuticals, Wayne, NJ). Cine and LGE imaging were obtained in 8 to 14 matching short-axis slices (8-mm thickness, zero gap) and 3 radial longaxis views of the LV.
CMR Analysis
All images were analyzed off-line with validated software (MASS Research Package, Leiden, The Netherlands) at the consensus of 2 investigators blinded to clinical data and outcome. LV volumes and LVEF (indexed to body surface area) were obtained via manual tracing of end-diastolic and end-systolic contours. Papillary muscles were considered part of the LV cavity and were not included in LV mass. After manual tracing of endocardial and epicardial borders on LGE images, total LGE and PIZ was defined based on a signal-intensity threshold of 2 to 3 SDs above the remote reference (normal) myocardium with a slice-by-slice designation of reference signal intensity to account for changes in intensity over time. 11 The LGE and PIZ mass were expressed in grams. Infarct size was expressed as a percentage of LV mass (%LGE), whereas PIZ size was quantified as a percentage of the total LGE mass (%PIZ). PIZ mass and %PIZ were not communicated to the referring physicians at the time of study reporting.
Follow-Up of Clinical Events
Clinical follow-up after CMR was first obtained via mailed questionnaire, electronic hospital records, and contact with the patients' physicians. Patients were then contacted by telephone if the mailed questionnaire was not returned. The Social Security Death Index was used to confirm all cases of patient death. We identified (1) death from any cause as the primary outcome and (2) death or appropriate defibrillator discharge for ventricular tachyarrhythmia (death/ICD), whichever occurred first, as the secondary outcome. A patient death was considered cardiac if preceded by an acute MI, decompensated heart failure, or documented fatal arrhythmia. Any unexpected death without a noncardiac pathogenesis was considered cardiac. As per established guidelines, any death that occurred within 1 hour of symptom onset without an obvious noncardiac cause was considered SCD. 13
Statistical Analysis
Continuous and categorical variables were compared by the Student t test or Wilcoxon rank-sum test (depending on data normality) and Fisher exact test, respectively. Event-free survival for the overall cohort and for the LVEF >35% subgroup stratified by above-and below-median %PIZ was analyzed by Kaplan-Meier methods (using a log-rank test). Univariable association between clinical and CMR covariates with the primary and secondary outcomes was assessed by Cox proportional hazards regression modeling. To address the incremental association of %PIZ beyond historical risk markers of CAD mortality, we constructed a multivariable model including patient age, LVEF, right ventricular ejection fraction (RVEF), and prolonged QT interval (corrected QT >440 ms; model 1). %LGE and %PIZ were then separately added into this model to assess their incremental prognostic association with patient mortality (model 2 and model 3). Incremental value was assessed with the net reclassification improvement (NRI) and relative integrated discrimination index evaluated at 4.2 years. 14 Confidence intervals (CIs) for both NRI and integrated discrimination index were determined by bootstrapping with 1000 samples. The categorical NRI was determined using 1% and 3% per year thresholds to define low-, intermediate-, and highrisk subgroups. In each of these 3 models, the validity of proportional hazards assumption was tested for all covariates in each model by including a time-dependent interaction term of each covariate with log survival time for each covariate in the model. A 2-sided P<0.05 was considered statistically significant. All statistical analysis was performed with SAS version 9.2 (SAS Institute, Cary, NC).
Results
Baseline Characteristics
Of the initial consecutive 317 patients in this study, clinical follow-up was successful in 311 patients (98%). Ten patients (3%) were excluded from the study group because of inadequate image quality or severe claustrophobia. The remaining 301 patients formed the study cohort. Seventy-eight patients of the current cohort with chronic CAD and LV dysfunction overlapped with a prior report from our group. 11 CMR was performed on a 1.5-T and a 3-T system in 231 (77%) and 70 (27%) patients, respectively. Baseline characteristics of patients stratified by LVEF (above or below 35%) are summarized in Table 1 . The study cohort had a mean age of 62 years and was predominantly male (76%). One third of the patients had a history of diabetes mellitus, and 64% had a previous MI. The mean LVEF was 41±14%, and mean RVEF was 50±13%. Patients with LVEF >35% were less likely to have diabetes mellitus, previous MI, heart failure, or use angiotensin-converting inhibitors or angiotensin receptor blockers. Patients with LVEF >35% also had a lower resting heart rate and were less likely to have prolonged intervals of QRS or corrected QT, or pathological Q waves. On CMR, patients with LVEF >35% had lower LV mass, lower LV end-diastolic and end-systolic volume index, and a higher RVEF. Patients with LVEF >35% were less likely to have LGE relative to the entire cohort. There was no significant difference in %PIZ across LVEF strata.
Clinical Follow-Up
During a median clinical follow-up of 3.9 years (range, 1-9.4 years), there were 66 deaths (22%), among them 44 cardiac deaths with 13 SCD. Patients who died were older and had a higher prevalence of comorbid conditions (such as diabetes mellitus or prior MI). They had lower LVEF, larger LGE mass, and higher incidence of QT interval prolongation on ECG. Patients who died also had substantially greater mean PIZ mass (5.9 versus 3.0 g, P<0.001) and %PIZ (29.4 versus 17.5%, P<0.0001). During study follow-up, 64 patients (mean LVEF 33±14%) received ICD implantation. Of these patients, 22 (34%) experienced appropriate ICD therapy for ventricular tachyarrhythmia. Two patients who experienced ICD therapy died during study follow-up. Additional characteristics of the study population stratified by vital status are displayed in Table I in the Data Supplement.
Unadjusted Association With Death and Death/ICD
Univariable predictors of all-cause mortality are shown in Table 2 . In the whole cohort, patient age, history of diabetes mellitus, prior MI, prolonged QT interval, LBBB, and both LVEF and RVEF by CMR were strongly associated with death. The presence of LGE was associated with a >3-fold and 2.5fold increased hazard of death and death/ICD, respectively (both P=0.007). However, %PIZ (per 10% of LGE mass) demonstrated stronger univariable association with death and death/ICD: 10% increment of %PIZ was associated with 27% and 20% increased hazard of death and death/ICD, respectively (P<0.0001 and P<0.001, respectively). In patients with LVEF >35% (N=196), %PIZ maintained robust univariable association with death and death/ICD, among other strong covariates including patient age, history of diabetes mellitus, and parameters of ventricular function. Kaplan-Meier survival curves, stratified by LVEF subgroups and median %PIZ, are illustrated in Figure 1A through 1C. Patients with LVEF >35% and low %PIZ (below median of 25%) had the best survival ( Figure 1A) . When stratified by median %PIZ, patients with LVEF >35% but high %PIZ (above median of 25%) had similarly reduced survival as those patients with LVEF ≤35% (P=0.88). Similar findings were observed when death/ICD was used as the outcome ( Figure 1B ). Among patients with LVEF >35%, %PIZ above median was independently associated with increased cardiac death (P=0.007; Figure 1C ). Univariable association with the secondary end point death/ICD is shown in Table II in the Data Supplement. Among all covariates considered, %PIZ demonstrated the strongest univariable association with cardiac death (hazard ratio=1.28, P=0.00085). We observed 22 cases of ventricular arrhythmias necessitating an appropriate ICD discharge, 9 of them among patients with LVEF >35%. %PIZ did not demonstrate a significant association with ventricular arrhythmias requiring ICD discharge in the whole cohort or the subset of patients with LVEF >35%.
One hundred ninety-nine patients had LVEF <50%, among them there were 55 (28%) and 71 (36%) cases of death and death/ICD during study follow-up, respectively. %PIZ maintained strong associations with both death and death/ICD in patients with LVEF <50%. Every 10% increment of %PIZ was associated with 29% and 19% increased hazard of death and death/ICD, respectively (P<0.001 and P=0.01, respectively). Figure 2 illustrates the annualized rate of all-cause death and death/ICD discharge in subgroups stratified by LVEF subgroups and median %PIZ. As expected, patients with LVEF ≤35% and %PIZ above median (25%) had the highest rates of death and death/ICD (20.3% and 25.4%, respectively). For patients with LVEF >35%, those with %PIZ above median experienced a markedly higher annual rate of death (12.2% versus 2.8%; P<0.0001) or death/ICD (13.2% versus 5.0%; P<0.001). Although rate of death and death/ICD are high in patients with LVEF <35%, those patients with %PIZ <median had more favorable outcomes of both death (13.8% versus 20.3%) and death/ICD (19.4% versus 25.4%), further highlighting the value of %PIZ even in patients deemed high risk by current LVEF criteria.
Annual Rates of Death and Death/ICD Stratified by LVEF Subgroups and Median %PIZ
Multivariable Association of Infarct Heterogeneity With Patient Death
Given the historical association between age, ventricular function, and baseline electrocardiographic features with mortality after MI, we built an additional multivariable model to assess the incremental association of myocardial scar (by %LGE) and tissue heterogeneity (by %PIZ) over these markers of risk. Accordingly, we successively added %LGE and %PIZ to known historical risk predictors (age, LVEF, RVEF, and prolonged QTc) in multivariable models for patient death for the overall population (Table 3) . When adjusted to these clinical variables, the addition of %LGE did not improve the Table 3 , model 1 versus model 2; P=0.59). However, when %PIZ was added into either model 1 or model 2, it demonstrated robust and independent association with patient death and provided significant improvement of model 1 and model 2 (Table 3 , model 1 or model 2 versus model 3; both P<0.001). Compared with model 1 and model 2, continuous NRI of model 3 was 0.404 (95% CI, 0.065-0.718) and 0.492 (95% CI, 0.183-0.817), respectively. These magnitude of these measures suggests a moderate to strong impact of %PIZ on risk assessment, independent of overall infarct size. Using clinically relevant categories of low (<1%/y), intermediate (1%-3%/y) and high risk (>3%/y), the NRI for model 3 compared with models 1 and 2 are 0.106 (95% CI, 0.022-0.188) and 0.105 (95% CI, 0.020-0.186). The relative integrated discrimination index, a sensitive measure of discrimination, for model 3 compared with models 1 and 2 is 0.289 (95% CI, 0.065-0.560) and 0.315 (95% CI, 0.094-0.590), indicated improved ability to distinguish those who will go on to have an event when %PIZ is considered. The proportional hazards assumption was tested valid for all multivariable models.
Discussion
The principal finding of this study is that infarct heterogeneity, as measured by %PIZ, is a novel and robust marker of all-cause death and death/ICD in patients with CAD and LV dysfunction.
This prognostic association was especially notable in patients with LVEF >35%, where every 10% increase in %PIZ portends a 25% increase in hazards of death after adjustment for common clinical risk markers. In addition, despite having an LVEF >35%, patients with a high degree of infarct heterogeneity experienced similar mortality as patients with severe systolic dysfunction (LVEF ≤35%). However, low infarct heterogeneity appeared to identify patients with LVEF >35% at low risk of death. The potential clinical impact of %PIZ is demonstrated in the significant improvements in risk discrimination and reclassification seen when this metric is added to clinical variables, systolic function parameters, and overall infarct size.
Current American College of Cardiology/American Heart Association guidelines have established LVEF as the clinical arbiter of ICD placement. 2 However, LVEF alone does not differentiate mortality because of pump failure or sudden death as a result of arrhythmia. 7 With rapid restoration of coronary flow by percutaneous intervention during acute MI being the standard of care, over 85% of survivors of acute MI have only mild or moderate reduction of LVEF in the recovered phase after infarction. 15 These factors highlight the importance of risk stratification in patients with CAD with LVEF >35% for potential life-saving therapies (ie, primary prevention ICD). Given the current paucity of methods of effective risk assessment in patients with LVEF >35%, the findings of our study support %PIZ as a novel marker of risk in patients with LVEF category where most SCD occur. Infarct heterogeneity has been implicated in the pathogenesis of sudden death on the basis of electrophysiological testing and histological analysis. 16 On histology, the PIZ is characterized by an interdigitation between viable myocytes and strands of fibrous tissue, the basis for electric re-entry. 17 Accordingly, electrophysiological mapping in the PIZ has revealed an endocardial activation pattern of circus movement re-entry through areas of surviving muscle fibers. Therefore, the PIZ may be a substrate for ventricular arrhythmia. The findings of this work complement the existing growing literature using quantitative LGE imaging as a marker of post-MI death. 18, 19 Multiple single-center and multicenter studies have demonstrated a strong prognostic association between infarct size and death, incremental to LVEF, in patients with high-risk CAD. [20] [21] [22] These papers, however, did not assess the prognostic implication of infarct tissue heterogeneity. Although LGE identifies core infarcted tissue, CMR assessment of the PIZ identifies the variegated signal intensities within infarcted tissue thought to be the nidus for ventricular tachyarrhythmia. 23, 24 Several groups have independently demonstrated an intimate association between the PIZ and arrhythmogenicity independent of infarct size by LGE and LVEF. 10, 12 Our group previously reported on 144 patients with prior MI, demonstrating that the PIZ strongly predicts all-cause death independent of severity of LV dysfunction and LGE size. 11 These results have been confirmed by other small single-center studies. 25, 26 There remains controversy within the CMR literature about which postprocessing criteria should be used to characterize the size of the PIZ. The peri-infarct tissue although described to manifest arrhythmogenic potentials during electrophysiological testing in numerous studies, 27,28 its extent is not readily characterizable by histological staining. Given this limitation in studying the PIZ, we think that associating the PIZ with relevant cardiac hard outcomes as performed in this study represents the most important method in studying the clinical relevance of CMR infarct heterogeneity. Furthermore, this study highlights that novel quantification of infarct heterogeneity by PIZ may provide unique prognostic information in patients with chronic CAD and reduced LV function, across a spectrum of LVEF. Specifically, the finding of robust risk stratification in patients with LVEF >35% may signify a potential role of noninvasive imaging of infarct heterogeneity in clinical trials evaluating ICD therapy aiming to reduce the total burden of SCD.
Limitations
Several limitations exist in the current study. First, our study was not adequately powered to assess the association of %PIZ with SCD. Although we did assess for SCD based on the classic definition of any death that occurs within 1 hour of symptom onset, only a small number of patient deaths could be confirmed to meet this definition. Clinically it is often difficult to obtain information on timing of deaths relative to clinical symptomatology, especially in cases of out-of-hospital death. We, therefore, decided to study all-cause mortality as a transportable end point. Second, use of ICD therapy as an outcome is inherently limited by the inability to causally link ventricular arrhythmia with arrhythmic mortality. Moreover, we may not have detected ventricular arrhythmia in patients who had not been implanted with an ICD. Third, our study cohort was limited by the exclusion of patients with implanted defibrillators or permanent pacemakers, severe renal dysfunction, or decompensated heart failure at the time of the CMR. Although this selection bias reduced the representation of the sickest patients with ischemic cardiomyopathy, we think the observation that infarct heterogeneity may have important prognostic implication, remains intriguing. Finally, there remains considerable heterogeneity in published criterion used to measure PIZ without vigorous histopathologic validation. 12, 25 We decided a priori to use SD-based criterion in quantifying infarct heterogeneity in keeping with our prior published work. 11
Conclusions
In this consecutive patient cohort with long-term follow-up, CMR-based infarct heterogeneity demonstrated a robust association with patient death incremental to LVEF and LGE, extending to patients with LVEF >35%. Incorporating CMR measurement of infarct heterogeneity as a criteria for antiarrhythmia device therapy in post-MI patients should be tested in clinical trials prospectively.
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